Active Not RecruitingNCT05434156

ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression

This active not recruiting study focuses on depression and currently lists sites or participation links in United Kingdom.

DepressionOtherFrom 18 Years to 65 Years

In plain English

Key information made simple

This study exists to better understand the safety of the medication ELE-101 and how manageable it feels in practice. Researchers are trying to understand how people respond to the medication ELE-101 in practice and what may need to be adjusted. For people living with Depression, the gap between what sounds good on paper and what works in daily life is often important. If the findings are useful, they could help future care become more targeted, practical, and easier to trust. Taking part helps build the evidence that can improve understanding and care for others over time.

What to expect

Your next step

The official record suggests in-person participation through a lab, with sites including MAC Clinical Research in Liverpool and MAC Clinical Research in Manchester. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually being able to understand the study and consent and matching the main diagnosis, while common reasons not to take part include active substance or alcohol problems that could affect the results and major medical issues that could make participation unsuitable. This is an early-stage study, which usually means a smaller group and a focus on learning how the approach behaves.

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Open source record

Interested?

Check my eligibility

Study reference: NCT05434156. Your email is the only field you need to provide here.

In practice

For you

Taking part may give access to a new approach being evaluated.

It requires regular visits and structured follow-up.

Requires travel, with in-person participation in United Kingdom.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com